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Introduction
Head and neck cancers represent approximately 2-4% of all malignancies in the United States, with an annual incidence of 35,720 new cases, 90% of them are squamous cell carcinoma (1) . At diagnosis, accurate staging has a prognostic value and is important in selecting the appropriate treatment strategy. After therapy, early detection of recurrence is critical to achieve an optimal outcome.
Computed tomography (CT) and magnetic resonance imaging (MRI) are the standard conventional imaging modalities for evaluation of patients with head and neck cancer. These tests, however, are based on morphologic diagnostic criteria, such as nodal size and contrast enhancement patterns that do not always accurately reflect the presence of active malignancy. Although imaging is important for assessing response after treatment of head and neck cancers as well as for early diagnosis of recurrence, the regional anatomy is distorted by surgery and/or radiation; this makes the distinction between post-treatment changes and recurrence or residual tumor difficult with imaging tests that rely on the forementioned morphologic criteria. In this specific clinical setting, CT and/or MRI have a known limited accuracy (2) .
Fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography (PET), a functional imaging modality plays an increasing role in the assessment of head and neck cancers, both for primary staging (3) as well as for post-therapy management (4, 5) . The use of PET is based on its capability to assess the metabolic status of tumors. PET has proved superior to both CT and MRI in diagnosing and differentiating recurrence from post radiation effects and surgical scars in sites of tumors of the head and neck (6, 7) . PET is superior to CT and MRI in the detection of cervical lymph node status in cases of head and neck cancer (8) .
However, PET is limited by the lack of anatomic landmarks, and the precise localization of suspicious findings is difficult due to the low background tracer uptake. In addition, variable degrees of physiologic and inflammatory non cancer-related uptake of FDG in the region of the head and neck mainly after treatment can confound interpretation of suspicious foci.
The combined imaging modality of PET/CT makes it possible to sequentially acquire PET and CT in a single imaging session with fusion of clinically significant anatomic and metabolic data. Preliminary studies have shown that PET/CT im-proves the anatomic localization of FDG-avid abnormalities and reduces the number of equivocal PET interpretations in selected tumors of the head and neck (9) .
Patients and methods

Patients
Sixty three patients (51 men and 12 women, mean age 58 years) with head and neck squamous cell carcinoma had 83 combined FDG-PET/CT and CT examinations at the department of Diagnostic Radiology and Nuclear Medicine, McGill University Health Centre in collaboration with the National Cancer Institute, Cairo University between September 2007 and June 2010.
Forty five PET/CT studies performed as a pre treatment staging for 45 patients who had not received any previous treatment. Thirty-eight PET/CT studies performed for 18 patients who had previous treatment, including 28 studies for suspected locoregional recurrence, four studies for suspected distant metastases, and six studies for treatment response to therapy (Table 1) .
To maintain homogeneity of the statistical analysis, we separated the 45 patients who had not received any treatment and the PET/CT done for pretreatment staging as one group and the other 18 patients who previously treated as another group.
First group
In the first group, PET/CT study done for American Joint Committee on Cancer (AJCC) TNM staging and for radiotherapy planning. At the time of PET/CT imaging, no patients had clinical or radiologic evidence of distant metastases or synchronous tumors by CT of the head and neck and chest X-ray.
In this group, we studied the diagnostic and therapeutic impact of the PET/CT on the management of the head and neck squamous cell carcinoma compared with the morphologic CT examination. Specifically, we looked for how PET/CT altered the TNM staging and the treatment plan.
Second group
This group includes the 18 patients who had received previous treatment. PET/CT done for suspected locoregional recurrence, suspected distant metastases, and treatment monitoring. Thirty-eight post treatment PET/CT studies were performed on average 8 weeks after completing definitive radiation therapy.
Patients were followed up for a minimum of 4 months (range 4-24 months). Biopsy, imaging follow-up (including PET/CT and CT), and clinical follow-up were all used as a standard references for determining the presence or absence of a tumor and the accuracy of the CT and PET/ CT studies.
CT and PET-CT findings classified as true positive (TP, positive imaging study confirmed as presence of cancer), true negative (TN, normal study with no further evidence of cancer), false positive (FP, positive imaging study with no evidence of cancer), or false negative (FN, normal study with further proven cancer).
Methods
2.
2.1. Imaging 2.2.1.1. FDG-PET/CT. Informed consent for PET/CT was obtained from all patients. Leukocytic count, C-reactive protein and body temperature were monitored to exclude the presence of acute inflammation.
Patients instructed to fast for 4-6 h prior to scanning. Blood glucose level was measured prior to injection. Patients with elevated blood glucose level more than 11 mmol (200 mg)/dL were not scanned. Patients were rested for a period of about 60 min in comfortable chair and instructed to minimize any talking, chewing, swallowing, or movement of the head, because these activities can influence muscular uptake in the masticator muscles, tip of the tongue, face, neck, and larynx.
PET/CT imaging was performed by the (Discovery STE 16, General Electric Medical System). Whole body PET and non contrast-enhanced CT imaging from the skull base to the upper thigh was performed approximately 1 h after intravenous injection of 8-15 mCi (296-555 MBq) of fuorodeoxyglucose (FDG). A limited breath-holding at normal expiration was done to avoid motion-artifacts and to match co-registration of CT and PET images in the area of the diaphragm. CT was acquired to perform transmission correction for the PET using the following parameters: 140 kV, 120-240 mAs and slice thickness 1.25 mm. PET images (axial field 90 cm, slice thickness 1.25 mm, four to five bed positions/patient, one head and neck position, 5 min/bed position,) were reconstructed with and without attenuation correction.
The PET scans were corrected for attenuation with coefficients obtained by scaling the CT numbers from the CT scans to PET energy level (511 kV). Attenuation correction based on the CT attenuation coefficient, is computed by using VUE Point HD algorithms. The helical CT scans were reconstructed into 512 · 512 images with a slice thickness to match those of the PET scans (1.25 mm).
2.2.1.2. CT. CT was done 2-4 weeks before the PET/CT using Multislice CT (GE Light speed, VCT 64). CT parameters were; pitch of 0.969, mAs (autosmart), 120-140 kVp, noise index 12, field of vision (FOV) 25 cm, 2.5 mm slice thickness, interval 1.25, 0°gantry tilt, and matrix 512 · 512. Scan zone was from the skull base to the aortic arch with sagittal and coronal reformatting.
A contrast material (Omnipaque, GE healthcare) (70-80 mL, 1.5 cc/s, and 45 s delay) was intravenously injected in all patients unless contraindicated because of severe allergy to the contrast material.
2.2.1.3. Image interpretation. The target of evaluation was set at the primary head and neck region, neck lymph node region for the CT and PET/CT examinations, and the whole-body for the PET/CT examinations. CT and fused PET/CT images interpreted by radiologist and nuclear medicine physician who were blinded to the other modality. Each reviewer had access to multiplanar reconstructions and to all prior clinical and radiologic data, including prior PET/CT if present.
For the visual and semi-quantitative interpretation of head and neck PET/CT scans, metabolically active foci (standardized uptake value (SUV) >3) in the lymph drainage regions were assessed to determine whether these were consistent with lymph nodes disclosed by morphological PET/CT and whether subsequent nodal upstaging or downstaging was necessary compared with the morphometric diagnosis. In morphometric terms, a cervical LN was considered to be involved if it showed rim or heterogeneous enhancement, or if it measured 10 mm or more in the short axis, regardless of enhancement pattern (10) .
Visual and semi-quantitative interpretation of the wholebody PET/CT scans (SUV >3) performed to establish how often PET/CT revealed metabolically active foci in the infraclavicular region that were consistent with morphological PET/ CT findings indicative of distant metastases or a simultaneous second primary tumor.
In the first group, all PET/CT findings were compared with pre-treatment staging in terms of TNM classification to assess PET/CT diagnostic and therapeutic impact. In the second group, the PET/CT findings were compared with the standard of references.
Standard of reference
Histological results used as a standard reference in the first group. The following criteria were accepted as standard of reference in the second group: (a) histopathological findings; (b) obvious clinical findings; (c) the combination of negative clinical findings, negative findings of other imaging studies, or negative follow-up findings; (d) resolution of the apparent abnormalities at subsequent PET/CT studies without intervening therapy together with negative clinical follow-up findings; and (e) the combination of positive clinical findings at the time of PET/CT and the resolution of the tumor after radiotherapy and chemotherapy.
In patients with suspected tumor recurrence, the final diagnosis was confirmed either by biopsy or clinically. Active malignancy was excluded by negative biopsy, negative repeated imaging results, or negative follow-up. Findings suspicious for the presence of distant metastases, or second primary cancers were confirmed by either histological or by combination of additional imaging studies and clinical follow-up. 
Statistical analysis
For the first group, descriptive statistics were calculated using medCalc version 7.0.0.2 (11) . Because this was an exploratory study, no inferential statistical methods were used.
For the second group, the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy were calculated for both CT and PET/CT. The differences in performance of both modalities were compared with the Chi-Square tests including Pearson Chi-Square and Fisher's Exact tests (12) (13) (14) as appropriate, with P values less than 0.05 considered to be statistically significant. Measurement of agreement is also calculated using the Kappa values (15).
End point
For the first group, the end point was to assess the diagnostic impact of PET/CT compared with the pre-treatment morphological imaging. A second end point was to determine the therapeutic impact of FDG-PET/CT in terms of changes to the initial treatment plan or modifications to radiotherapy. Nodal upstaging or downstaging as suggested by PET/CT was taken into account in treatment planning and RT was modified in terms of volume and dose by adapting the boost volume to metabolically active foci while simultaneously intensifying the dose in these areas. For both groups, the discovery of distant metastases prompted revision of the initial treatment strategy and intention from curative to palliative. Diagnosis of a simultaneous second primary tumor necessitated formulation of an individual treatment strategy, principally along curative lines, once metastatic spread had been excluded.
In the event of solitary infraclavicular findings and a suspected second primary tumor, findings were confirmed by histology and in cases with multiple infraclavicular foci and suspected metastases further imaging clarification was performed. After appropriate benefit-risk analysis, metabolically active cervical LNs were not subjected to further histological assessment.
Results
First group
Diagnostic impact
PET/CT detected distant metastases for the first time in five (11.1%) patients. A second primary tumor was detected in three (6.6%). Active FDG uptake was detected in the rectum in one patient (proved adenocarcinoma), and FDG uptake in the rectum and the liver (proved rectal adenocarcinoma with liver metastasis) in the second patient. The third patient had gastric fundal adenocarcinoma with liver metastasis ( Table 2) .
Compared with the morphological CT findings, nodal status based on metabolic activity was upstaged in 12 (26.6%) ( Fig. 1 ) and downstaged in three (6.6%) patients. Compared with the CT findings, the total TNM staging changed in 23 (51.1%) patients. Upstaged in 19 (42.2%) and downstaged in four (8.8%) patients (Table 3) .
On the basis of the information yielded by PET/CT, treatment strategy was modified from curative to palliative in five (11.1%). Because of the diagnosis of a second primary, three (6.6%) patients received additional curative therapy as part of an interdisciplinary treatment strategy. In the light of PET/CT, changes in the nodal status based on metabolic activity resulted in modification of radiotherapy volume and dose in 11 (24.4%) patients. Overall, PET/CT resulted in treatment change or radiotherapy modification in 19 (41.7%) patients (Table 4 ).
Second group
Diagnostic impact
Thirty-eight CT studies were reviewed. CT defined 28 (73.7%) studies as positive and 10 (26.3%) as negative. There were 20 true positive, eight false positive, three true negative, and seven false negative studies. The Pearson Chi-Square value was 0.007 and P value 0.932 and the P value by Fisher's Exact was 1.0. The Kappa value was 0.014 with P value 0.932 denoting very week agreement between the CT and the standard of references.
Thirty-eight PET/CT studies were reviewed. PET/CT defined 26 (68.4%) studies as positive and 12 (31.6%) as negative. There were 25 true positive, one false positive, 10 true negative, and two false negative studies. The Pearson Chi-Square value was 25.222 and P < 0.001 and the P value by Fisher's Exact was <0.001. The Kappa value was 0.813 with P value <0.001 denoting strong agreement between the PET/CT and the standard of references.
The false positive case on PET/CT was patient with squamous cell carcinoma of the nasopharynx, with mild uptake at level II lymph node that was thought to be nodal recurrence, proved negative on biopsy.
One false negative case on PET/CT is seen in patient with recurrent tonsillar carcinoma after resection and neck dissection, showing a necrotic lymph node with no activity. Biopsy showed metastatic SCC (Fig. 2) . The other false positive case was a base of tongue carcinoma after radiotherapy and chemotherapy, showing mild residual uptake thought to represent residual tumor and resolved on follow-up with no treatment.
The diagnostic accuracy of the CT and PET/CT for the study-based statistical analysis is shown in (Tables 5 and 6).
Therapeutic impact
PET/CT altered further clinical management in seven (18.4%) patients. Biopsy or fine needle aspiration had been planned based on clinical examination and radiologic data suspicious of recurrence and was canceled because of negative PET/CT results (Fig. 3) .
PET/CT induced a change in the planned therapeutic approach in nine (23.6%). One patient had initially supraglottic SCC was diagnosed to have distant pancreatic and liver metastases, so treatment plan changed from curative to palliative. Two patients were diagnosed to have second primary adenocarcinoma of the rectum, so proper rectal carcinoma management was initiated. PET/CT guided biopsy from a specific metabolically active area inside an edematous region in six patients (three larynx, two nasopharynx, and one oropharynx) decreased the chances for tissue sampling errors and avoided damage to non malignant tissue. Biopsy was positive for malignancy in all of the six patients.
Discussion
The use of FDG as a tracer is based on Warburg's discoveries that cancer cells are partial anaerobes and ferment sugar by producing lactate; thus a considerable proportion of the energy developed by cancer cells is derived not from oxidation but from fermentation (16) . The reduced energy yield by comparison with oxidation is compensated for by an increase in glucose metabolism. Glucose uptake here is dependent on the expression of glucose transporters, on the activity of hexokinases that regulate entry into the glycolytic pathway, and on cell proliferation of the tissue studied. Tissue hypoxia activates the transcription of glucose transporters via hypoxia-inducible factor (17) .
Imaging is an important clinical tool in the evaluation of patients with head and neck cancer. CT modalities rely on morphologic criteria such as nodal size and contrast enhancement pattern that does not always accurately reflect the presence of active malignant conditions. The reported sensitivity, specificity, and accuracy of CT for diagnosis of cervical nodal metastases were 88%, 86%, and 87%, respectively (18) , and specificity dropped further when the 10 mm size criterion was used, to 39% for CT and 48% for MRI (19) .
FDG-PET plays an increasing role in the diagnosis and management planning of head and neck cancer. Hybrid PET/CT has promoted the field of molecular imaging in head and neck cancer. This modality is particularly relevant in the head and neck region, given the complex anatomy and variable physiologic FDG uptake patterns. The vast majority of PET/ CT applications in head and neck cancer related to head and neck squamous cell carcinoma. Clinical applications of PET/ CT in the head and neck cancer include diagnosis of distant metastases, detection of synchronous second primaries, detection of carcinoma of unknown primary and detection of residual or recurrent disease. Emerging applications are precise delineation of the tumor volume for radiation treatment planning, monitoring treatment, and providing prognostic information.
Accurate staging at the time of diagnosis is the most important factor for treatment planning and determination of prognosis. One attractive feature of PET as a modality for initial TNM staging is that it covers most of the body within single study. PET therefore provides information on the primary tumor, nodal metastases, distant metastases, and potential second primary carcinomas. A literature survey on the use of PET in head and neck cancer compared to CT indicates that PET has a higher sensitivity (87% versus 62%) and specificity (89% versus 73%) for cancer staging. Addition of PET/CT to the initial staging of patients with head and neck cancers has a measurable impact on the treatment selection (20) .
According to the data in the published literature, the incidence of distant metastases at the time of the initial diagnosis of head and neck cancers are low, with reported figures ranging from 1.6% to 4.2%. Ultimately this is the basis for the recommendation from the national comprehensive cancer network (NCCN) that systemic staging should be limited to chest X-ray and optional chest CT. This minimal staging is usual in clinical practice and has been applied in several prospective randomised clinical studies (21) .
In a retrospective analysis of 600 patients with head and neck cancer, Dietl et al. detected distant metastases in only 4.8% of patients at initial cancer diagnosis, in 19% of patients during the further course of illness, and in 24.2% of patients in stage IV disease; the steep rise in metastatic disease during the first 12 months suggested a clinically silent process of metastasis at an earlier point in time (22) .
The use of additional pre-treatment diagnostic modalities with increased sensitivity results in a higher detection rate for metastatic disease. Thus, at the time of the initial diagnosis, distant metastases are detectable in 17% of patients by routine chest CT, and in 21% of patients by extended field PET (23) .
The role of PET for staging of distant metastases in head and neck cancer is acknowledged as one of the most powerful indication. There is a general agreement that PET is indicated for initial staging when there is suspicious of distant metastases and synchronous second tumor. The incidence of distant metastases increases with locally advanced (T3-T4), N2, or N3 disease, extracapsular extension of the lymph node disease, and perineural invasion (24) .
Distant metastases considerably limit overall survival, which may range from 4.3 to 8.2 months from the time when metastatic disease is first diagnosed. There is no adequate salvage therapy, and the Karnofsky performance status is crucial. This tends to be adversely affected by the toxicity of inappropriate curative therapy, and it is therefore vital for the initial treatment strategy to be defined correctly (25) .
In the first group of our patients, FDG-PET/CT detected distant metastases for the first time in five (11.1%) patients.
On the basis of the information yielded by PET/CT, treatment strategy was modified from curative to palliative therapy. In the second group of our patients, one patient had initially supraglottic SCC was diagnosed to have distant pancreatic and liver metastases, so treatment plan changed from curative to palliative one. In Dietl et al. study, PET/CT detected six (17.1%) out of the 35 included patients to have distant metastases and all are confirmed by further imaging (26) . In Gordin et al. study, PET/CT diagnosed distant metastases in seven out of the 90 patients, which changed the treatment protocol from curative to palliative and ruled out distant metastases suspected by CT in 10 patients, so they received definitive treatment (27) .
The incidence of second primary tumors with simultaneous, synchronous or metachronous manifestation is reported to be as high as 16%; in most cases these second malignancies are associated with exposure to harmful agents, and include bronchial carcinomas, other head and neck malignancies or esophageal carcinomas. PET and PET/CT have proven useful for detection of second primary tumors in the head and neck and elsewhere in the body in patients with previously treatment head and neck SCC being evaluated for recurrence (28) .
In our first group, second primary tumor detected in three (6.6%) patients. Active FDG uptake was detected in the rectum in one patient (proved adenocarcinoma), and in the rectum and the liver (proved rectal adenocarcinoma with liver metastasis) in the second patient. The third patient had gastric fundal adenocarcinoma with liver metastasis. Because of the diagnosis of a second primary, the three patients received additional curative therapy as part of an interdisciplinary treatment strategy. In the second group, two patients were diagnosed to have second primary adenocarcinoma of the rectum, so proper rectal carcinoma management was initiated. Fleming et al. described 123 patients with head and neck cancers initially staged with FDG-PET/CT and the prevalence of second cancers in their population was 4.9% (29) . Goerres et al. found four second primaries in 34 patients with oral SCC, resulting in prevalence of synchronous primaries of 12% (30) . In Dietl et al. study, PET/CT detected four (11.4%) out of the 35 included patients to have second primaries, two bronchial carcinoma and two esophageal carcinoma, all confirmed by pathology (26) .
Lymph node metastases reduce survival by 50%, with the prognosis in this context depending on factors such as the number of lymph nodes infiltrated, level of infiltration, extracapsular spread, and the resectability (31) . Macroscopic LN metastases require surgical resection, or they should be included in the boost volume and irradiated with a tumoricidal dose of at least 70 Gy. Otherwise the result is relatively under-dosing with the risk of tumor progression or local recurrence (32) . As with distant metastases, there is also no adequate salvage therapy available for local recurrence, and the two year survival rate following treatment for recurrence is 25% (33) .
The diagnosis of infiltration and hence also the definition of target volume is usually based on criteria provided by morphological imaging techniques. Their sensitivity and specificity in the evaluation of the N0 neck range from 14% to 83% and from 78% to 100%, respectively (34) . The sensitivity and specificity of PET/CT in the assessment of cervical LNs range from 80% to 90% and from 88% to 100%, respectively, and are therefore superior to those of morphological imaging techniques (35) .
In our study's first group, compared with the morphological CT findings, nodal status based on metabolic activity by PET/CT was upstaged in 12 (26.6%) ( Fig. 1 ) and downstaged in three (6.6%) patients. The total TNM staging changed in 23 (26) .
Comparing our results to the Dietl et al. study, on the basis of the information yielded by PET/CT, treatment strategies were modified from curative to palliative in five (11%) compared to six (17.1%) patients because of the diagnosis of distant metastases. Because of the diagnosis of second primary tumor added further curative treatment for three (6.6%) patients compared to two (5.7%) patients. The changes in nodal status based on metabolic activity results in modification of radiotherapy volume and dose in 11 (24 (26) .
Surgery and radiation therapy alter the normal head and neck anatomy. Treatment-related edema, fibrosis, inflammation, and scarring are limiting factors that further hamper the performance of physical examination and CT or MRI imaging in the diagnosis of recurrent head and neck cancer. Numerous studies have shown that PET/CT can detect residual or recurrent disease with more accuracy than conventional imaging ranging from 92% to 97% (27) .
In our study, the diagnostic accuracy of PET/CT is significantly superior to the CT accuracy in patients with head and neck squamous cell carcinoma for assessment of treatment response and recurrent disease, with sensitivity, specificity, PPV, NPV and accuracy of 92.6%, 90.9%, 96.2%, 83.3%, and 92.1%, respectively, for PET/CT, and 74.1%, 27.3%, 71.4%, 30.0%, and 60.5%, respectively, for CT. Gordin et al. reported sensitivity, specificity, PPV, NPV, and accuracy 89%, 95%, 94%, 90%, and 92%, respectively, for PET/CT, compared with 92%, 18%, 51%, 71%, and 54%, respectively, for conventional cross sectional imaging (27) . Klabbers et al. reviewed studies published between 1994 and early 2003 regarding the utility of 18 F-FDG PET for detection of residual and recurrent head and neck cancers after radiotherapy. The results showed better sensitivity of the 18 F-FDG PET (86%) and specificity (73%) compared with CT and/or MRI sensitivity (56%) and specificity (59%), respectively (37) .
Ha et al. study included 108 patients and found that 18 F-FDG PET/CT detected persistent or recurrent head and neck SCC with a sensitivity of 82%, a specificity of 92%, PPV of 64%, NPV of 97%, and an overall accuracy of 90% (38) .
In our study, the significantly lower specificity for CT (27.3%) as compared with PET/CT (90.9%) supports the previous reports that showed the low yield of CT in the evaluation of locoregional recurrence of the head and neck cancer (39) . The inability of the CT to distinguish between the post treatment edema and the local recurrence is the cause of the eight false positive studies in our study (Fig. 3) . A positive PET/ CT accurately guides biopsy to the hypermetabolic foci in an edematous and scared region as demonstrated in six patients and thus achieved two goals; decrease sampling errors, and less damage to normal but edematous structures.
PET/CT has a high impact on patient care in the head and neck cancers. Ha et al. reported that PET/CT altered the treatment plan in 31% of the patients with primary head and neck SCC. The treatment plan was modified in 24% of our second group patients. Most of them had advanced stages III and IV disease that require a combined therapy approach. Accurate staging and early detection of recurrence can improve the outcome of these patients (38) .
Although biopsy is the gold standard for diagnosis of recurrence, it can cause additional edema, pain, chondroradionecrosis, additional costs, and emotional stress (40) . In our study, long term clinical follow-up was the gold standard in this clinical scenario and results in 10 PET/CT studies defined as true positive and two false positive compared to three true negative and seven false positive for CT. One PET/CT false negative was normal in CT scan, the other case had necrotic lymph node that did not show FDG uptake but was positive for metastasis on biopsy ( Fig. 2) . Of the 10 patients, seven were assessed for tumor recurrence, two for treatment response, and the other one for distant metastasis. Current results indicate therefore that in patients with a negative PET/CT study, a biopsy can be at least temporarily postponed unless there is a high clinical suspicion for recurrent disease.
The utility of anatomical imaging in the post treatment situation is limited because of fibrosis, tissue edema, and anatomical distortion. The early detection of residual or recurrent head and neck cancer following radiation therapy and/or chemotherapy poses a diagnostic challenge. A survey of the literature showed that 18 F-FDG PET is the most sensitive non invasive modality presently available for differentiating post treatment changes from residual or recurrent disease (41) .
Ong et al. demonstrated in their study that included 65 patients that PET/CT has high negative predictive value and specificity (87% and 89%, respectively.) for excluding residual locoregional disease after chemoradiotherapy and that neck dissection may be omitted safely in patients without lymphadenopathy, while in patients with residual lymphadenopathy, a lack of abnormal 18 F-FDG uptake in these nodes also excludes viable tumor with high certainty but still further assessment is needed (40) . In our study PET/CT had a negative predictive value 83.3% and specificity 90.9%, respectively.
PET and PET/CT have a high sensitivity and moderate specificity for detecting recurrent disease at the primary tumor site, regional lymph node metastases, and distant metastases. Wong performed a meta-analysis on the studies published between 1999 and 2002 that showed relatively high sensitivity (84-100%) and moderate specificity (61-93%) regarding the 18 F-FDG PET in recurrent HNSCC (42) .
The tumor delineation by PET/CT compared with the pathology was investigated by Halpern et al. who included 49 patients in his study. A patient-by-patient analysis yielded a sensitivity of 88%, a specificity of 78%, and an accuracy of 86% for PET/CT compared to the pathology (43).
Conclusion
PET/CT is an imaging modality with high diagnostic performance in the assessment of head and squamous cell carcinoma, and induced a significant change in the management of the study population. In the first group, FDG-PET/CT yielded additional diagnostic information in 44.4% of patients, with subsequent modification of treatment strategy in 11.1% and implementation of further curative therapy in 6.6%. Based on the findings of PET/CT, modification of radiotherapy was performed in 24.6% of patients in this group. In the second group, study-based analysis results in PET/CT sensitivity 92%, specificity 90.9%, positive predictive value 96.2%, negative predictive value 83.3%, and total accuracy 92.1%, compared with 74.1%, 27.3%, 71.4%, 30.0%, and 60.5% for CT, respectively. PET/CT altered further clinical management in 18.4% patients and induced a change in the planned therapeutic approach in 23.6%.
